At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
CellFX Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Prospective, Treat and Resect Feasibility Study of the CellFX System for the Treatment of Low-Risk Basal Cell Carcinoma (BCC) Lesions
In Brief
A clinical study evaluating CellFX System for BCC - Basal Cell Carcinoma and 2 related conditions. Completed, enrolled 30 participants across 5 sites.
Detailed Summary
This prospective, multicenter, study is designed to evaluate the safety and effectiveness of the CellFX System in adults subjects with low-risk basal cell carcinoma (superficial and nodular) for complete histological clearance of the target lesion followed by surgical tumor excision 60 days post-treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBCC - Basal Cell Carcinoma, BCC, Excision Margin
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartJun 2021
First PostedJun 2021
Primary CompletionMar 2022
Study CompletionJul 2022
TodayJul 2026
First PostedJun 8, 2021
Enrollment StartJun 2, 2021
Primary CompletionMar 2, 2022
Study CompletionJul 22, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.1 years ago
Interventions
CellFX Systemdevice
Nano-Pulse Stimulation (NPS)